guest ::
| Home > Publications database > Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening. > print |
| Home > Publications database > Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening. > print |
| 001 | 298341 | ||
| 005 | 20250129163506.0 | ||
| 024 | 7 | _ | |a 10.3791/67593 |2 doi |
| 024 | 7 | _ | |a pmid:39868688 |2 pmid |
| 037 | _ | _ | |a DKFZ-2025-00245 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Wang, Changwen |0 P:(DE-He78)be724b82903aa397737196d8200edb30 |b 0 |e First author |
| 245 | _ | _ | |a Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening. |
| 260 | _ | _ | |a Cambridge, MA |c 2025 |b JoVE |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738152276_9464 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A240#LA:A240# |
| 520 | _ | _ | |a Glioblastoma (GBM) is described as a group of highly malignant primary brain tumors and stands as one of the most lethal malignancies. The genetic and cellular characteristics of GBM have been a focal point of ongoing research, revealing that it is a group of heterogeneous diseases with variations in RNA expression, DNA methylation, or cellular composition. Despite the wealth of molecular data available, the lack of transferable pre-clinic models has limited the application of this information to disease classification rather than treatment stratification. Transferring the patients' genetic information into clinical benefits and bridging the gap between detailed descriptions of GBM, genotype-phenotype associations, and treatment advancements remain significant challenges. In this context, we present an advanced human GBM organoid model, the Laboratory Engineered Glioblastoma Organoid (LEGO), and illustrate its use in studying the genotype-phenotype dependencies and screening potential drugs for GBM. Utilizing this model, we have identified lipid metabolism dysregulation as a critical milestone in GBM progression and discovered that the microsomal triglyceride transfer protein inhibitor Lomitapide shows promise as a potential treatment for GBM. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 2 | |a Glioblastoma: genetics |2 MeSH |
| 650 | _ | 2 | |a Glioblastoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Organoids: metabolism |2 MeSH |
| 650 | _ | 2 | |a Organoids: drug effects |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: genetics |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Drug Screening Assays, Antitumor: methods |2 MeSH |
| 650 | _ | 2 | |a Drug Evaluation, Preclinical: methods |2 MeSH |
| 700 | 1 | _ | |a Stöffler, Nadja |0 P:(DE-He78)79d514e9270d1a0c8b17992db50542f1 |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Liu, Haikun |0 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6 |b 2 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.3791/67593 |g no. 215, p. 67593 |0 PERI:(DE-600)2975343-0 |p e67593 |t JoVE journal |v 215 |y 2025 |x 1940-087X |
| 909 | C | O | |o oai:inrepo02.dkfz.de:298341 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)be724b82903aa397737196d8200edb30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)79d514e9270d1a0c8b17992db50542f1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JOVE-J VIS EXP : 2019 |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-05-04 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-05-04 |
| 920 | 2 | _ | |0 I:(DE-He78)A240-20160331 |k A240 |l A240 Molekulare Neurogenetik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A240-20160331 |k A240 |l A240 Molekulare Neurogenetik |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)A240-20160331 |k A240 |l A240 Molekulare Neurogenetik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A240-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|